Denise Rageot

934 total citations
19 papers, 640 citations indexed

About

Denise Rageot is a scholar working on Molecular Biology, Organic Chemistry and Inorganic Chemistry. According to data from OpenAlex, Denise Rageot has authored 19 papers receiving a total of 640 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 8 papers in Organic Chemistry and 5 papers in Inorganic Chemistry. Recurrent topics in Denise Rageot's work include PI3K/AKT/mTOR signaling in cancer (11 papers), Asymmetric Hydrogenation and Catalysis (5 papers) and Quinazolinone synthesis and applications (3 papers). Denise Rageot is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (11 papers), Asymmetric Hydrogenation and Catalysis (5 papers) and Quinazolinone synthesis and applications (3 papers). Denise Rageot collaborates with scholars based in Switzerland, Germany and Canada. Denise Rageot's co-authors include Florent Beaufils, Matthias P. Wymann, Doriano Fabbro, Andreas Pfaltz, Anna Melone, Alexander Sele, Petra Hillmann, Thomas Bohnacker, David H. Woodmansee and Benoı̂t Pugin and has published in prestigious journals such as Angewandte Chemie International Edition, Nature Communications and Cancer Research.

In The Last Decade

Denise Rageot

19 papers receiving 628 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Denise Rageot Switzerland 13 373 269 127 57 53 19 640
Cornelis P. Vlaar Puerto Rico 14 476 1.3× 229 0.9× 46 0.4× 29 0.5× 33 0.6× 44 812
Philipp Janser Switzerland 12 248 0.7× 147 0.5× 55 0.4× 85 1.5× 65 1.2× 13 538
Daniela Angst Switzerland 9 167 0.4× 98 0.4× 45 0.4× 86 1.5× 60 1.1× 13 390
Matthew C. Lucas United States 16 159 0.4× 220 0.8× 24 0.2× 37 0.6× 18 0.3× 32 530
Norbert Schmees Germany 11 281 0.8× 288 1.1× 117 0.9× 6 0.1× 14 0.3× 19 870
Karla Bravo‐Altamirano United States 15 310 0.8× 434 1.6× 214 1.7× 9 0.2× 18 0.3× 20 755
Anna Melone Switzerland 11 337 0.9× 165 0.6× 16 0.1× 57 1.0× 51 1.0× 18 523
Rémy Morgentin France 13 292 0.8× 301 1.1× 15 0.1× 33 0.6× 30 0.6× 23 624
Joy Bauch United States 12 456 1.2× 172 0.6× 11 0.1× 53 0.9× 58 1.1× 20 751
Nicola M. Heron United Kingdom 15 420 1.1× 336 1.2× 70 0.6× 35 0.6× 16 0.3× 31 940

Countries citing papers authored by Denise Rageot

Since Specialization
Citations

This map shows the geographic impact of Denise Rageot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denise Rageot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denise Rageot more than expected).

Fields of papers citing papers by Denise Rageot

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Denise Rageot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denise Rageot. The network helps show where Denise Rageot may publish in the future.

Co-authorship network of co-authors of Denise Rageot

This figure shows the co-authorship network connecting the top 25 collaborators of Denise Rageot. A scholar is included among the top collaborators of Denise Rageot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Denise Rageot. Denise Rageot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Meyer, Claudio F., Pierre Boulay, Matthias P. Wymann, et al.. (2022). Stereospecific Synthesis of Substituted Sulfamidates as Privileged Morpholine Building Blocks. Synthesis. 55(3). 499–509. 1 indexed citations
2.
3.
Borsari, Chiara, Denise Rageot, Thomas Bohnacker, et al.. (2019). A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor. Journal of Medicinal Chemistry. 62(18). 8609–8630. 30 indexed citations
4.
Fabbro, Doriano, Denise Rageot, Florent Beaufils, et al.. (2019). Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD. Neuropharmacology. 162. 107812–107812. 14 indexed citations
5.
Rageot, Denise, Florent Beaufils, Chiara Borsari, et al.. (2019). Scalable, Economical, and Practical Synthesis of 4-(Difluoromethyl)pyridin-2-amine, a Key Intermediate for Lipid Kinase Inhibitors. Organic Process Research & Development. 23(11). 2416–2424. 7 indexed citations
6.
Tarantelli, Chiara, Eugenio Gaudio, Petra Hillmann, et al.. (2019). The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax. Cancers. 11(6). 775–775. 12 indexed citations
7.
Rageot, Denise, Thomas Bohnacker, Erhan Keleş, et al.. (2019). (S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase. Journal of Medicinal Chemistry. 62(13). 6241–6261. 49 indexed citations
8.
Borsari, Chiara, Denise Rageot, Florent Beaufils, et al.. (2019). Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl–Pyrimidine Moiety. ACS Medicinal Chemistry Letters. 10(10). 1473–1479. 34 indexed citations
9.
10.
11.
Bohnacker, Thomas, A.E. Prota, Florent Beaufils, et al.. (2017). Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention. Nature Communications. 8(1). 14683–14683. 86 indexed citations
12.
Beaufils, Florent, Vladimir Cmiljanović, Thomas Bohnacker, et al.. (2017). 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. Journal of Medicinal Chemistry. 60(17). 7524–7538. 115 indexed citations
13.
Rageot, Denise, Florent Beaufils, Anna Melone, et al.. (2017). Abstract 140: Discovery and biological evaluation of PQR530, a highly potent dual pan-PI3K/mTORC1/2 inhibitor. Cancer Research. 77(13_Supplement). 140–140. 3 indexed citations
14.
Hillmann, Petra, Denise Rageot, Florent Beaufils, et al.. (2017). Abstract 159: Pharmacological characterization of the selective, orally bioavailable, potent dual PI3K/mTORC1/2 inhibitor PQR530. Cancer Research. 77(13_Supplement). 159–159. 3 indexed citations
15.
Rageot, Denise & Andreas Pfaltz. (2012). Chiral Proline‐Based P,O and P,N Ligands for Iridium‐Catalyzed Asymmetric Hydrogenation. Helvetica Chimica Acta. 95(11). 2176–2193. 12 indexed citations
16.
Rageot, Denise, et al.. (2012). Recent Advances in Iridium-Catalyzed Asymmetric Hydrogenation: New Catalysts, Substrates and Applications in Total Synthesis. CHIMIA International Journal for Chemistry. 66(4). 187–187. 9 indexed citations
17.
Rageot, Denise, David H. Woodmansee, Benoı̂t Pugin, & Andreas Pfaltz. (2011). Proline‐Based P,O Ligand/Iridium Complexes as Highly Selective Catalysts: Asymmetric Hydrogenation of Trisubstituted Alkenes. Angewandte Chemie International Edition. 50(41). 9598–9601. 71 indexed citations
18.
Rageot, Denise, David H. Woodmansee, Benoı̂t Pugin, & Andreas Pfaltz. (2011). Proline‐Based P,O Ligand/Iridium Complexes as Highly Selective Catalysts: Asymmetric Hydrogenation of Trisubstituted Alkenes. Angewandte Chemie. 123(41). 9772–9775. 28 indexed citations
19.
Vergès, Bruno, E Florentin, S. Baillot-Rudoni, et al.. (2008). Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes. Diabetologia. 51(8). 1382–1390. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cornelis P. Vlaar Breakdown of academic impact, for papers by Philipp Janser Breakdown of academic impact, for papers by Daniela Angst Breakdown of academic impact, for papers by Matthew C. Lucas Breakdown of academic impact, for papers by Norbert Schmees Breakdown of academic impact, for papers by Karla Bravo‐Altamirano Breakdown of academic impact, for papers by Anna Melone Breakdown of academic impact, for papers by Rémy Morgentin Breakdown of academic impact, for papers by Joy Bauch Breakdown of academic impact, for papers by Nicola M. Heron
Rankless by CCL
2026